108 related articles for article (PubMed ID: 19382401)
1. Bevacizumab in kidney cancer: new indication. Premature approval of this indication.
Prescrire Int; 2009 Feb; 18(99):10. PubMed ID: 19382401
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab: new indication. Metastatic breast cancer: many adverse effects.
Prescrire Int; 2008 Dec; 17(98):236. PubMed ID: 19422148
[No Abstract] [Full Text] [Related]
3. Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.
Prescrire Int; 2009 Feb; 18(99):11. PubMed ID: 19385126
[TBL] [Abstract][Full Text] [Related]
4. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
5. In focus: bevacizumab for renal cell carcinoma.
Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
[No Abstract] [Full Text] [Related]
6. Bevacizumab in breast cancer: the best is yet to come?
Puhalla S; Brufsky A
Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
[No Abstract] [Full Text] [Related]
7. [ASCO 2008. Bevacizumab in advanced renal carcinoma].
Mansueto G; Longo F
Tumori; 2008; 94(5):15-23. PubMed ID: 19112964
[No Abstract] [Full Text] [Related]
8. Bevacizumab: improved survival at what cost?
Kolesar JM
Am J Health Syst Pharm; 2005 May; 62(10):1017. PubMed ID: 15901584
[No Abstract] [Full Text] [Related]
9. Avastin's uncertain future in breast cancer treatment.
Twombly R
J Natl Cancer Inst; 2011 Mar; 103(6):458-60. PubMed ID: 21393607
[No Abstract] [Full Text] [Related]
10. Optimizing outcomes with bevacizumab by better targeting patients and tumors.
DeMichele A; Fox KR
Oncology (Williston Park); 2009 Apr; 23(4):339-40. PubMed ID: 19476263
[No Abstract] [Full Text] [Related]
11. Bevacizumab and recurrent malignant gliomas: a European perspective.
Wick W; Weller M; van den Bent M; Stupp R
J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
[No Abstract] [Full Text] [Related]
12. Anti-VEGF therapy for renal cell carcinoma.
Escudier B
Clin Adv Hematol Oncol; 2007 Jul; 5(7):530-1. PubMed ID: 17679926
[No Abstract] [Full Text] [Related]
13. Targeted drugs for metastatic renal cell carcinoma.
Motzer RJ; Basch E
Lancet; 2007 Dec; 370(9605):2071-3. PubMed ID: 18156012
[No Abstract] [Full Text] [Related]
14. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(9):1-4. PubMed ID: 17061399
[No Abstract] [Full Text] [Related]
15. Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma.
Bukowski RM
Nat Rev Clin Oncol; 2009 May; 6(5):253-4. PubMed ID: 19390549
[TBL] [Abstract][Full Text] [Related]
16. Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours.
Van Der Horst-Schrivers AN; Slot MH; Willemse PH; Kema IP; De Vries EG; Wymenga AN
Acta Oncol; 2008; 47(1):153-5. PubMed ID: 17851877
[No Abstract] [Full Text] [Related]
17. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs.
Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526
[No Abstract] [Full Text] [Related]
18. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
Mir O; Mouthon L; Alexandre J; Mallion JM; Deray G; Guillevin L; Goldwasser F
J Natl Cancer Inst; 2007 Jan; 99(1):85-6. PubMed ID: 17202119
[No Abstract] [Full Text] [Related]
19. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
Chamberlain MC
Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
[No Abstract] [Full Text] [Related]
20. Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
Prescrire Int; 2008 Aug; 17(96):145. PubMed ID: 19489184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
